{"url":"https://lda.senate.gov/api/v1/filings/d8b5c6ba-395e-47ce-9cc3-c5c8d3d4bbf9/","filing_uuid":"d8b5c6ba-395e-47ce-9cc3-c5c8d3d4bbf9","filing_type":"Q3","filing_type_display":"3rd Quarter - Report","filing_year":2021,"filing_period":"third_quarter","filing_period_display":"3rd Quarter (July 1 - Sep 30)","filing_document_url":"https://lda.senate.gov/filings/public/filing/d8b5c6ba-395e-47ce-9cc3-c5c8d3d4bbf9/print/","filing_document_content_type":"text/html","income":"11250.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"James W. Rock","dt_posted":"2021-10-31T14:47:49.883000-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"4103 Avenue H","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"Austin","registrant_state":"TX","registrant_zip":"78751","registrant":{"id":33545,"url":"https://lda.senate.gov/api/v1/registrants/33545/","house_registrant_id":30422,"name":"ROCK & ASSOCIATES","description":"Government relations consultant.","address_1":"517 C Street, NE","address_2":null,"address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20002","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"JAMES W. ROCK","contact_telephone":"+1 703-627-8226","dt_updated":"2025-02-03T11:57:31.624210-05:00"},"client":{"id":141945,"url":"https://lda.senate.gov/api/v1/clients/141945/","client_id":176,"name":"PRECISION PHARMACY","general_description":"Compounding Pharmacy.","client_government_entity":false,"client_self_select":null,"state":"CA","state_display":"California","country":"US","country_display":"United States of America","ppb_state":"CA","ppb_state_display":"California","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2016-06-01"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Issues related to the NASEM report to the FDA on compounded bioidentical hormones, and issues related to GFI #256 on animal drug compounding.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":22837,"prefix":null,"prefix_display":null,"first_name":"JAMES","nickname":null,"middle_name":"W","last_name":"ROCK","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"Issues related to Appropriations and report language funding the FDA, specifically as it relates to animal drug compounding.  No bill numbers yet.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":22837,"prefix":null,"prefix_display":null,"first_name":"JAMES","nickname":null,"middle_name":"W","last_name":"ROCK","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"PHA","general_issue_code_display":"Pharmacy","description":"Issues related to animal drug compounding.  No specific legislation yet.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":22837,"prefix":null,"prefix_display":null,"first_name":"JAMES","nickname":null,"middle_name":"W","last_name":"ROCK","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}